Literature DB >> 8478502

Comparison of full-dose versus half-dose pharmacotherapy in the maintenance treatment of recurrent depression.

E Frank1, D J Kupfer, J M Perel, C Cornes, A G Mallinger, M E Thase, A B McEachran, V J Grochocinski.   

Abstract

Recent evidence points to the prophylactic efficacy of maintaining recurrent unipolar patients on the same dose of antidepressant medication that was used to treat the acute episode (Frank et al., 1990; Kupfer et al., 1992). Therefore, the question of whether such patients should be tapered to a lower maintenance dose after successful resolution of an acute episode is clearly important. In this report we describe a small randomized clinical trial in which patients were assigned to either full-dose or half-dose maintenance treatment for a period of 3 years. Survival analysis suggests that superior prophylaxis can be achieved with a full-dose as compared to a half-dose maintenance treatment strategy (p < 0.07). Mean survival time for the full-dose subjects was 135.17 (SE 19.75) weeks as compared to 74.94 (SE 19.78) weeks (median of 43.1 weeks) for the half-dose subjects. We conclude that for patients who have suffered several recurrences, full-dose maintenance treatment is the more effective prophylactic strategy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8478502     DOI: 10.1016/0165-0327(93)90001-z

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  10 in total

Review 1.  Continuation and maintenance therapy of early-onset major depressive disorder.

Authors:  Graham J Emslie; Taryn L Mayes; Maryse Ruberu
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

2.  Measuring the severity of depression and remission in primary care: validation of the HAMD-7 scale.

Authors:  Roger S McIntyre; Jakub Z Konarski; Deborah A Mancini; Kari A Fulton; Sagar V Parikh; Sophie Grigoriadis; Larry A Grupp; David Bakish; Marie-Josee Filteau; Chris Gorman; Charles B Nemeroff; Sidney H Kennedy
Journal:  CMAJ       Date:  2005-11-22       Impact factor: 8.262

3.  Management of resistant depression.

Authors:  L Warneke
Journal:  Can Fam Physician       Date:  1996-10       Impact factor: 3.275

Review 4.  A risk-benefit assessment of pharmacotherapies for clinical depression in children and adolescents.

Authors:  J Renaud; D Axelson; B Birmaher
Journal:  Drug Saf       Date:  1999-01       Impact factor: 5.606

5.  Selective serotonin reuptake inhibitors. Unsuccessful treatment may be related to non-response or non-compliance.

Authors:  J A Henry; A S Hale
Journal:  BMJ       Date:  1994-10-22

Review 6.  Effective treatment for mental disorders in children and adolescents.

Authors:  B J Burns; K Hoagwood; P J Mrazek
Journal:  Clin Child Fam Psychol Rev       Date:  1999-12

7.  Cost effectiveness of fluvoxamine in the treatment of recurrent depression in France.

Authors:  M Nuijten; L Hadjadjeba; C Evans; J van den Berg
Journal:  Pharmacoeconomics       Date:  1998-10       Impact factor: 4.981

8.  Remission rates with milnacipran 100 mg/day and 150 mg/day in the long-term treatment of major depression.

Authors:  Kazuo Okumura; Toshiaki A Furukawa
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

Review 9.  Treatment of recurrent depression: a sequential psychotherapeutic and psychopharmacological approach.

Authors:  Giovanni A Fava; Chiara Ruini; Nicoletta Sonino
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

10.  Anxiety and Depression: Optimizing Treatments.

Authors:  James C. Ballenger
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2000-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.